587 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
3. Using the methylome to predict pre-eclampsia
4. Plasma metabolites are altered before and after diagnosis of preeclampsia or fetal growth restriction
5. Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
6. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
7. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia
8. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
9. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
10. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
11. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
12. Investigating ticagrelor in a preclinical pipeline as a novel therapeutic to prevent preterm birth.
13. DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
14. Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria
15. NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
16. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
17. The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin
18. Characterising side population genes in placentas from patients with preeclampsia and/or fetal growth restriction.
19. The Brain Natriuretic Peptide (BNP) system is expressed in the placenta and vasculature in preeclampsia: potential implications for novel therapeutic strategies
20. Upregulation of placental Ski-like proto-oncogene in preterm preeclampsia: potential target for preeclampsia treatment?
21. Circulating trace elements for the prediction of preeclampsia and small for gestational age babies
22. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
23. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
24. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
25. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
26. MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
27. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity
28. Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
29. Circulating chemerin is elevated in women with preeclampsia
30. Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth
31. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
32. Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
33. Screening circulating proteins to identify biomarkers of fetal macrosomia
34. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion
35. In vitro investigation into the regulation and function of SPINT1, a biomarker for fetal growth restriction
36. Therapeutic intervention to alleviate long-term cardiovascular risk following preeclampsia
37. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model
38. Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth
39. Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro
40. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
41. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
42. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity.
43. Endothelial protein C receptor is increased in preterm preeclampsia and fetal growth restriction
44. Placental galectin-3 is reduced in early-onset preeclampsia
45. Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development
46. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
47. Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction
48. Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
49. Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
50. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.